BioSpace News Archive

Immatics N.V. (Nasdaq: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Editas Medicine, Inc. (Nasdaq: EDIT, “Editas Medicine”), a leading genome editing company, today announced that the two companies have entered into a strategic research collaboration and licensing agreement to combine gamma-delta Treatment for cancer.

Pinnacle Fertility (Pinnacle), the fastest-growing network of physician-centered fertility practices representing more than seven clinics and 20 locations nationwide, has partnered with Igenomix as their exclusive preimplantation genetics testing (PGT) laboratory and provider for genetic counseling services.

Rapid growth in the field of information technology has brought in a rise in the demand for hospital administration software for the medical industry.

Wilmington, Delaware, United States: The gastric cancer drugs market is expected to garner exceptional growth during the forecast period of 2020-2030 on the back of the rising cases of gastric cancer across the globe.

Wilmington, Delaware, United States: An early toxicity testing or screening is the process of safety assessment which determines the level of tissue or cell damage and maximum safe concentration of any chemical or drug.

Wilmington, Delaware, United States: Blood pressure can be defined as a force that is exerted by flowing blood on the walls of vessels as heart pumps it.

Wilmington, Delaware, United States: The global molecular spectroscopy market is expected to observe promising growth across the assessment period of 2020-2030.

Bavarian Nordic A/S announced that the Public Health Agency of Canada will be purchasing IMVAMUNE® smallpox vaccine at a value of approximately USD 56 million.

OSE Immunotherapeutics SA and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation, presented four posters featuring neoepitope specific immunotherapy Tedopi® in various cancer indications at the American Society of Clinical Oncology Annual Meeting held June 4 – 7.

Sensorion announces, that the initiation of a Proof of Concept clinical trial of SENS-401 in patients scheduled for cochlear implantation has been approved by regulatory authorities in France.